Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2023 07:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to...
October 09, 2023 08:04 ET | Source: The Insight Partners

Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners

Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
June 06, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Propulsion of Hepatitis B Virus Infection Clinical Trial Pipeline as Novel and Extensive 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

New York, USA, June 06, 2023 (GLOBE NEWSWIRE) -- Propulsion of Hepatitis B Virus Infection Clinical Trial Pipeline as Novel and Extensive 90+ Therapies Likely to Enter in the Treatment Domain |...
March 16, 2023 07:30 ET | Source: Arbutus Biopharma Corporation

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical...
June 08, 2022 07:34 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been...
March 05, 2018 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference

INDIANAPOLIS, March 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
February 05, 2018 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference

INDIANAPOLIS, , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
November 08, 2017 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences to Present at the Jefferies London Healthcare Conference

INDIANAPOLIS, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
October 02, 2017 07:00 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces 2017 AASLD Presentations

INDIANAPOLIS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
February 16, 2017 07:05 ET | Source: Assembly Biosciences, Inc.

Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations

INDIANAPOLIS, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...

Next Page keyboard_arrow_right